Business Development Manager – Immunoassays & Biomarkers (EMEA)

About the role

Spear Bio is seeking top‑performing Business Development Managers to introduce its ultra‑sensitive immunoassay platform to Life Sciences and CRO customers across the EMEA region. The role will focus on neurodegenerative disease research markets, leveraging an existing network of Big Pharma, biotech, CRO and academic contacts. You will be based in Europe (e.g., London or Germany) and travel 30‑40% of the time.

Key responsibilities

• Deliver sales presentations and demos to promote Spear Bio’s value proposition.
• Drive kit and assay service sales, building a pipeline for senior managers.
• Manage customer logistics, including demos, information sharing and technical follow‑up.
• Utilise existing high‑level scientific network in Big Pharma, biotech, CROs and academia.
• Achieve and exceed revenue quotas and market‑share targets in the assigned territory.
• Provide technical support to Key Opinion Leaders and gather Voice of Customer feedback for R&D.
• Collaborate with US marketing, custom assay services and internal teams to generate leads and refine sales plans.
• Monitor competitive landscape and develop strategies to win market share.

Required profile

• MS or PhD in Biology, Biochemistry, Bioengineering or related field with 6‑12+ years of technical sales or business development experience in ultrasensitive immunoassays or neurology IVD products.
• Clear, proactive communicator with strong commercial acumen, high energy and a bias for action.
• Proven ability to ask strategic questions, present technology solutions and translate customer feedback into actionable strategies.
• Willingness to travel up to 30‑40% for customer engagement and industry events.

Required skills

• Ultrasensitive immunoassay technology knowledge.
• IVD product expertise, including LDTs.
• Understanding of neuroscience market dynamics.

What we offer

• Competitive compensation.
• Meaningful stock ownership.
• Comprehensive benefits.
• Great work environment in a high‑growth biotech startup.